Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Differentially expressed genes analysis between dihydroberberine, sunitinib and dihydroberberine plus sunitinib.

ABSTRACT: To gain insights into the mechanisms of dihydroberberine, sunitinib and dihydroberberine plus sunitinib on inhibition to A549 cells, we have employed whole genome microarray expression profiling as a discovery platform to identify different genes between dihydroberberine, sunitinib and dihydroberberine plus sunitinib-treated sample and control.

ORGANISM(S): Homo sapiens

PROVIDER: GSE70282 | GEO | 2015/06/26

SECONDARY ACCESSION(S): PRJNA288152

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Similar Datasets

Differentially expressed genes analysis between dihydroberberine, sunitinib and dihydroberberine plus sunitinib.

Project description:To gain insights into the mechanisms of dihydroberberine, sunitinib and dihydroberberine plus sunitinib on inhibition to A549 cells, we have employed whole genome microarray expression profiling as a discovery platform to identify different genes between dihydroberberine, sunitinib and dihydroberberine plus sunitinib-treated sample and control. A549 cells were cultivated in the absence or presence of 25?mol/L dihydroberberine, 2?mol/L sunitinib, 25?mol/L dihydroberberine plus 2?mol/L sunitinib for 48 h, followed by the Agilent Whole Human Genome Oligo Microarray

2015-06-26 | E-GEOD-70282 | biostudies-arrayexpress

Analysis of Gene Expression of Human Renal Cell Carcinoma by DNA Microaray in Patients treated with Sunitinib. An Exploratory Study

Project description:Gene Evaluation of DNA expression from snap-frozen renal cell cancer tissue from 5 patients with locally advanced non-metastatic tumors, submitted to nephrectomy after being treated with 2 cycles of neoadjuvant Sunitinib were compared to match controls comprising of 6 patients with no neoadjuvant intervension using microarray platform Affymetrix Human Genome U133 Plus 2.0 containing 54675 probes. Validation followed using qRT-PCR Exploratory, prospective evaluation of gene expression in renal cell tumor snap frozen tissue after neoadjuvant Sunitinib compared to a control group with no neoadjuvant treatment

2015-05-11 | E-GEOD-68629 | biostudies-arrayexpress

Differentially expressed genes analysis between Eupolyphaga sinensis Walker (ESW) and Taspine derivate

Project description:To gain insights into the mechanisms of Eupolyphaga sinensis Walker (ESW) and taspine derivate on inhibition to HCC, we have employed whole genome microarray expression profiling as a discovery platform to identify different genes between ESW-treated sample and control. At the same time, the differences were investigated between taspine derivate and the same control. SMMC-7721 cells were cultivated in the absence or presence of 0.1mg/mL ESWE and Taspine derivate of 2.5x10-5mol/L for 48 h, followed by the Agilent Whole Human Genome Oligo Microarray. The PLG, PKCβ and IL3RA genes confirmation of Microarray analysis was confirmed by Real-time PCR.

2013-11-21 | GSE52554 | GEO

Impact of sunitinib resistance on clear cell renal cell carcinoma therapeutic sensitivity in vitro

Project description:Sunitinib resistance creates a major clinical challenge for the treatment of advanced clear cell renal cell carcinoma (ccRCC) and functional and metabolic changes linked to sunitinib resistance are not fully understood. We sought to characterize the molecular and metabolic changes induced by the development of sunitinib resistance in ccRCC by developing and characterizing the transcriptome of two human ccRCC cell lines resistant to sunitinib.

2024-04-17 | GSE216494 | GEO

Analysis of Gene Expression of Human Renal Cell Carcinoma by DNA Microaray in Patients treated with Sunitinib. An Exploratory Study

2015-05-11 | GSE68629 | GEO

Differentially expressed genes analysis between Eupolyphaga sinensis Walker (ESW) and Taspine derivate

Project description:To gain insights into the mechanisms of Eupolyphaga sinensis Walker (ESW) and taspine derivate on inhibition to HCC, we have employed whole genome microarray expression profiling as a discovery platform to identify different genes between ESW-treated sample and control. At the same time, the differences were investigated between taspine derivate and the same control. SMMC-7721 cells were cultivated in the absence or presence of 0.1mg/mL ESWE and Taspine derivate of 2.5x10-5mol/L for 48 h, followed by the Agilent Whole Human Genome Oligo Microarray. The PLG, PKCM-NM-2 and IL3RA genes confirmation of Microarray analysis was confirmed by Real-time PCR. SMMC-7721 cells were cultivated in the absence or presence of 0.1mg/mL Eupolyphaga sinensis Walker extract (ESWE) and Taspine derivate of 2.5x10-5mol/L for 48 h, followed by the Agilent Whole Human Genome Oligo Microarray

2013-11-21 | E-GEOD-52554 | biostudies-arrayexpress

CM214 - Biomarker Analysis From the Phase 3 CheckMate 214 Trial of Nivolumab Plus Ipilimumab (N+I) or Sunitinib (S) in Advanced Renal Cell Carcinoma (aRCC)

Project description:CM214 - Biomarker Analysis From the Phase 3 CheckMate 214 Trial of Nivolumab Plus Ipilimumab (N+I) or Sunitinib (S) in Advanced Renal Cell Carcinoma (aRCC)

| EGAS00001005501 | EGA

miRNA array of clear cell renal cell carcinoma from patients treated with sunitinib

Project description:A multiple receptor tyrosine kinase inhibitor, sunitinib, is a first-line therapy for clear cell renal cell carcinoma (CCRCC). Unfortunately, it has the major challenges of low initial response rate and resistance after about one year of treatment. Here we evaluated a microRNA (miRNA) and its target responsible for sunitinib resistance. Using miRNA profiling, we identified miR-96-5p upregulation in tumors from sunitinib-resistant CCRCC patients

2021-12-03 | GSE189331 | GEO

MicroRNA expression in peripheral blood predicts poor and prolonged response to sunitinib.

Project description:Peripheral blood samples were taken before initiation of therapy and 2 weeks later from patients with advanced renal cell carcinoma treated with sunitinib in first line. MicroRNA expression in peripheral blood was assessed using microarrays and several models predicting poor response and prolonged response to sunitinib were constructed and evaluated. Peripheral blood samples obtained before initiation of therapy with sunitinib and 14 days later were used to assess expression values of miRNAs.

2013-02-11 | E-GEOD-32099 | biostudies-arrayexpress

Effect of depletion of FUS on gene expression during in sunitinib-resistance cell lines

Project description:To investigate the function FUS in the regulation of sunitinib-resistance， we used lentiviral transduction to knock down FUS expression in the sunitinib-resistant RCC cells.

2023-03-31 | GSE226245 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data